Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies

Vaxcyte, Inc.

Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.
Placement agent receives up to 3.00% compensation on gross proceeds from sales.
Terminated prior sales agreement with Jefferies under which $270.3M had been sold.
Company not obligated to sell any shares; no assurance of any sales under new agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.